Nebenwirkungen · Repatha
Repatha 140 mg solution for injection in pre-filled syringe Repatha 140 mg solution for injection in pre-filled pen Repatha 420 mg solution for injection in cartridge · Abschnitt 4.8 · PDF-Seite 6
HOS-131152 · Präparat HOS-097013
The safety profile was consistent between subjects with post-baseline LDL-C < 25 mg/dL (0.65 mmol/L) or < 40 mg/dL (1.03 mmol/L) compared to subjects with higher post-baseline LDL-C (≥ 40 mg/dL [1.03 mmol/L]), with median (Q1, Q3) Repatha exposure of 84.2 (78.1, 89.8) months in subjects who continued on Repatha and 59.8 (52.8, 60.3) months in subjects on placebo who switched to Repatha in an open-label extension study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-04T12:30:00Z · SHA-256 d2505aa52199753458c8b299a339c2c3d9d330c34201edb39c0bf49997f26fba · Passage d38e789ea88d0a5296670ed7ee779e9bccd492347deb52a175109f29c8838866 · Zeichen 2275–2697 im Abschnitt